Los puntos clave no están disponibles para este artículo en este momento.
Tamoxifen (ICI 46474) was given by mouth to patients with advanced, recurrent, or metastatic breast carcinoma. At a dosage of 10 mg twice daily 60% of patients showed arrest or reversal of tumour growth. At a dosage of 20 mg twice daily 77% showed arrest or reversal of tumour growth. Side effects were usually trivial and their incidence was the same at both dose levels. No patients showed virilization of fluid retention.
H. W. C. Ward (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: